TORONTO, ON / ACCESSWIRE / May 3, 2021 / Noetic Foundry, an operating company building psychedelic biotechnology startups, is pleased to announce the appointment of Dr. Tim Piser as its Chief Scientific Officer.
Dr. Piser has over 25 years of neuroscience drug discovery and development expertise at both large pharmaceutical and early-stage biotechnology companies. His career has been driven by the overarching desire to develop novel medicines that improve the lives of patients.
Prior to joining Noetic Foundry, Dr. Piser was Chief Scientific Officer of Cadent Therapeutics, a Massachusetts-based clinical-stage biopharmaceutical company acquired by Novartis AG in December 2020 for up to $770 million. At Cadent, Dr. Piser led the discovery and development of multiple drugs for cognitive, movement, and mood disorders such as schizophrenia, essential tremor, spinocerebellar ataxia, and treatment-resistant depression.
Previously, Dr. Piser was Global Product Director at AstraZeneca, where he led the multidisciplinary team developing lanicemine (AZD6765), an NMDA antagonist program targeting treatment-resistant depression.
Naseem Saloojee, co-founder of Noetic Foundry, commented, “Tim’s significant pre-clinical and clinical neuroscience drug development experience will enable us to develop important medicines for the benefit of society. The combination of his unique pedigree and his passion for providing treatments that address unmet mental health needs is emblematic of our broader ethos at Noetic.”
Dr. Piser said, “While psychedelic drugs are the most potent psychoactive agents known to humankind, none have been approved for therapeutic use. Yet, an understanding is emerging of the therapeutic effect of these agents, from the binding of serotonin receptors to long-lasting changes in brain networks that subserve self-referential processing, which is impaired in all mental health disorders. Noetic Foundry is building a diverse portfolio of businesses to develop new and differentiated psychedelic and psychedelic-inspired therapies. The time is right for this effort.”
Dr. Piser holds a BSc in Biology from University of Delaware, and a PhD in Pharmacology from University of Minnesota, Twin Cities.
About Noetic Foundry
Noetic Labs Incorporated (dba Noetic Foundry) is a biotech operating company dedicated to building, organizing, and financing high potential projects in the psychedelic medicine and wellbeing space. The Noetic Foundry team brings extensive operational, scientific, and capital markets acumen, addressing key bottlenecks to the viability and scalability of promising, early-stage initiatives in psychedelic medicine. Learn more at noeticfoundry.com.
Noetic operates two venture capital funds, the first being Noetic Psychedelic Fund LP founded February 2020 and the second being Noetic Fund II Master Cayman, LP (dba Noetic Fund II). Both funds focus on supporting leading entrepreneurs and scientists in the nascent psychedelic biotechnology sector by investing in private companies addressing unmet needs in healthcare. Each company within the Noetic ecosystem has a separate governance structure, but shares the common mission of supporting projects that define a healthy future for people and the planet.